The Exchange has sought clarification from Sun Pharma Advanced Research Company Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted declaration in case of unmodified opinion(s) The response of the Company is awaited.
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Sun Pharma Advanced Research Company (SPARC) to explain why it did not submit a required declaration related to unmodified audit opinions for the quarter ended 31 March 2025. This request falls under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. An unmodified opinion means the auditors gave a clean/qualified-okay view on the company's financial statements, and listed companies must declare this. The company has not yet responded to the exchange, and its reply is awaited.
This is a routine procedural compliance query and not a penalty or investigation. Shareholders are unlikely to see any material impact on the stock unless the matter escalates due to a delayed or unsatisfactory response from the company.